Co-expression of Rho guanine nucleotide exchange factor 5 and Src associates with poor prognosis of patients with resected non-small cell lung cancer

He,Ping; Wu,Wei; Wang,Haidong; Liao,Kelong; Zhang,Wei; Xiong,Gang; Wu,Feng; Meng,Gang; Yang,Kang

doi:10.3892/or.2013.2797

Co-expression of Rho guanine nucleotide exchange factor 5 and Src associates with poor prognosis of patients with resected non-small cell lung cancer

Authors:
- Ping He
- Wei Wu
- Haidong Wang
- Kelong Liao
- Wei Zhang
- Gang Xiong
- Feng Wu
- Gang Meng
- Kang Yang
View Affiliations

Affiliations: Department of Cardiothoracic Surgery, Southwest Hospital, Third Military Medical University, 400038 Chongqing, P.R. China, Institute of Pathology, Southwest Cancer Center, Southwest Hospital, Third Military Medical University, 400038 Chongqing, P.R. China
Published online on: October 14, 2013 https://doi.org/10.3892/or.2013.2797
Pages: 2864-2870

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Specific and sensitive enough molecular biomarkers are lacking to accurately predict the survival of non-small cell lung cancer (NSCLC) patients. ARHGEF5 and Src have been shown to play an important role in tumorigenesis. However, the involvement of ARHGEF5 and Src in NSCLC remains unknown. Therefore, we evaluated the expression of ARHGEF5 and Src in resected NSCLC tissues and the correlation of co-expression of ARHGEF5 and Src and the prognosis of patients with resected NSCLC. Positive expression of ARHGEF5 was detected in 133 cases of 193 patients (68.91%). A total of 193 NSCLC patients (male: 145; female: 48; average age: 61.84 years; age range: 31-84) were enrolled in this study, of which 99 cases were squamous cell carcinomas (SCCs) (51.30%) and 94 cases were adenocarcinomas (ADCs) (48.70%). The expression of ARHGEF5 was mainly located in the cytoplasm of tumor cells, but not in the corresponding adjacent lung tissues. The levels of ARHGEF5 were significantly associated with age, differentiation and tumor stage. ARHGEF5 protein expression was associated with Src protein expression in NSCLC (χ2=11.874, P<0.01) and in ADC (χ2=12.194, P<0.01), but not in SCC. Co-immunoprecipitation revealed that there was a physical interaction between Src and ARHGEF5 in lung cancer cells. The patients with ARHGEF5(+)/Src(+) had a shorter survival time compared with the other patients (29.37 months versus 39.90 months, P=0.029). In conclusion, ARHGEF5/Src can be considered as a prognostic biomarker and a therapeutic target for patients with resected NSCLC.

View Figures

View References

1	Goya T, Asamura H, Yoshimura H, et al: Prognosis of 6644 resected non-small cell lung cancers in Japan: a Japanese lung cancer registry study. Lung Cancer. 50:227–234. 2005. View Article : Google Scholar : PubMed/NCBI
2	Lee SY, Kim MJ, Jin G, et al: Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers. J Thorac Oncol. 5:1734–1740. 2010. View Article : Google Scholar : PubMed/NCBI
3	Casas-Selves M, Kim J, Zhang Z, et al: Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition. Cancer Res. 72:4154–4164. 2012. View Article : Google Scholar : PubMed/NCBI
4	Ye YZ, Zhang ZH, Fan XY, et al: Notch3 overexpression associates with poor prognosis in human non-small-cell lung cancer. Med Oncol. 30:5952013. View Article : Google Scholar : PubMed/NCBI
5	Chan AM, McGovern ES, Catalano G, Fleming TP and Miki T: Expression cDNA cloning of a novel oncogene with sequence similarity to regulators of small GTP-binding proteins. Oncogene. 9:1057–1063. 1994.PubMed/NCBI
6	Takai S, Chan AM, Yamada K and Miki T: Assignment of the human TIM proto-oncogene to 7q33-->q35. Cancer Genet Cytogenet. 83:87–89. 1995. View Article : Google Scholar : PubMed/NCBI
7	Zheng Y: Dbl family guanine nucleotide exchange factors. Trends Biochem Sci. 26:724–732. 2001. View Article : Google Scholar : PubMed/NCBI
8	Hart MJ, Eva A, Evans T, Aaronson SA and Cerione RA: Catalysis of guanine nucleotide exchange on the CDC42Hs protein by the dbl oncogene product. Nature. 354:311–314. 1991. View Article : Google Scholar : PubMed/NCBI
9	Debily MA, Camarca A, Ciullo M, et al: Expression and molecular characterization of alternative transcripts of the ARHGEF5/TIM oncogene specific for human breast cancer. Hum Mol Genet. 13:323–334. 2004. View Article : Google Scholar : PubMed/NCBI
10	Xie X, Chang SW, Tatsumoto T, Chan AM and Miki T: TIM, a Dbl-related protein, regulates cell shape and cytoskeletal organization in a Rho-dependent manner. Cell Signal. 17:461–471. 2005. View Article : Google Scholar : PubMed/NCBI
11	Giaccone G and Zucali PA: Src as a potential therapeutic target in non-small-cell lung cancer. Ann Oncol. 19:1219–1223. 2008. View Article : Google Scholar : PubMed/NCBI
12	Kuroiwa M, Oneyama C, Nada S and Okada M: The guanine nucleotide exchange factor Arhgef5 plays crucial roles in Src-induced podosome formation. J Cell Sci. 124:1726–1738. 2011. View Article : Google Scholar : PubMed/NCBI
13	Li P, Zhang Z, Wang Q, et al: The ectopic expression of IFN regulatory factor 4-binding protein is correlated with the malignant behavior of human breast cancer cells. Int Immunopharmacol. 9:1002–1009. 2009. View Article : Google Scholar : PubMed/NCBI
14	Maaser K, Daubler P, Barthel B, et al: Oesophageal squamous cell neoplasia in head and neck cancer patients: upregulation of COX-2 during carcinogenesis. Br J Cancer. 88:1217–1222. 2003. View Article : Google Scholar : PubMed/NCBI
15	Sharma SV, Oneyama C, Yamashita Y, et al: UCS15A, a non-kinase inhibitor of Src signal transduction. Oncogene. 20:2068–2079. 2001. View Article : Google Scholar : PubMed/NCBI
16	Lazer G and Katzav S: Guanine nucleotide exchange factors for RhoGTPases: good therapeutic targets for cancer therapy? Cell Signal. 23:969–979. 2011. View Article : Google Scholar : PubMed/NCBI
17	Hou M, Tan L, Wang X and Zhu YS: Antisense Tiam1 down-regulates the invasiveness of 95D cells in vitro. Acta Biochim Biophys Sin. 36:537–540. 2004. View Article : Google Scholar : PubMed/NCBI
18	Hirata D, Yamabuki T, Miki D, et al: Involvement of epithelial cell transforming sequence-2 oncoantigen in lung and esophageal cancer progression. Clin Cancer Res. 15:256–266. 2009. View Article : Google Scholar : PubMed/NCBI
19	Fernandez-Zapico ME, Gonzalez-Paz NC, Weiss E, et al: Ectopic expression of VAV1 reveals an unexpected role in pancreatic cancer tumorigenesis. Cancer Cell. 7:39–49. 2005. View Article : Google Scholar : PubMed/NCBI
20	Lazer G, Idelchuk Y, Schapira V, Pikarsky E and Katzav S: The haematopoietic specific signal transducer Vav1 is aberrantly expressed in lung cancer and plays a role in tumourigenesis. J Pathol. 219:25–34. 2009. View Article : Google Scholar : PubMed/NCBI
21	Brantley-Sieders DM, Zhuang G, Vaught D, et al: Host deficiency in Vav2/3 guanine nucleotide exchange factors impairs tumor growth, survival, and angiogenesis in vivo. Mol Cancer Res. 7:615–623. 2009. View Article : Google Scholar : PubMed/NCBI
22	Serrano-Olvera A and Gerson R: Age associated survival rate in non small cell lung cancer. Gac Med Mex. 145:27–35. 2009.(In Spanish).
23	Salmeron D, Chirlaque MD, Isabel Izarzugaza M, et al: Lung cancer prognosis in Spain: the role of histology, age and sex. Respir Med. 106:1301–1308. 2012. View Article : Google Scholar : PubMed/NCBI
24	Xu W, Allbritton N and Lawrence DS: SRC kinase regulation in progressively invasive cancer. PLoS One. 7:e488672012. View Article : Google Scholar : PubMed/NCBI
25	Budde RJ, Ke S and Levin VA: Activity of pp60c-src in 60 different cell lines derived from human tumors. Cancer Biochem Biophys. 14:171–175. 1994.PubMed/NCBI
26	Mazurenko NN, Kogan EA, Zborovskaya IB and Kisseljov FL: Expression of pp60c-src in human small cell and non-small cell lung carcinomas. Eur J Cancer. 28:372–377. 1992. View Article : Google Scholar : PubMed/NCBI
27	Masaki T, Igarashi K, Tokuda M, et al: pp60c-src activation in lung adenocarcinoma. Eur J Cancer. 39:1447–1455. 2003. View Article : Google Scholar : PubMed/NCBI
28	Thomas SM and Brugge JS: Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol. 13:513–609. 1997. View Article : Google Scholar : PubMed/NCBI
29	Laird AD, Li G, Moss KG, et al: Src family kinase activity is required for signal tranducer and activator of transcription 3 and focal adhesion kinase phosphorylation and vascular endothelial growth factor signaling in vivo and for anchorage-dependent and -independent growth of human tumor cells. Mol Cancer Ther. 2:461–469. 2003.
30	Song L, Turkson J, Karras JG, Jove R and Haura EB: Activation of Stat3 by receptor tyrosine kinases and cytokines regulates survival in human non-small cell carcinoma cells. Oncogene. 22:4150–4165. 2003. View Article : Google Scholar : PubMed/NCBI
31	Eliceiri BP, Paul R, Schwartzberg PL, Hood JD, Leng J and Cheresh DA: Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol Cell. 4:915–924. 1999. View Article : Google Scholar : PubMed/NCBI
32	Sato M, Tanaka T, Maeno T, et al: Inducible expression of endothelial PAS domain protein-1 by hypoxia in human lung adenocarcinoma A549 cells. Role of Src family kinases-dependent pathway. Am J Respir Cell Mol Biol. 26:127–134. 2002. View Article : Google Scholar : PubMed/NCBI
33	Johnson FM, Bekele BN, Feng L, et al: Phase II study of dasatinib in patients with advanced non-small-cell lung cancer. J Clin Oncol. 28:4609–4615. 2010. View Article : Google Scholar : PubMed/NCBI
34	Haura EB, Tanvetyanon T, Chiappori A, et al: Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol. 28:1387–1394. 2010. View Article : Google Scholar : PubMed/NCBI